Publication date: Oct 08, 2019
CAMBRIDGE, Mass. –(Business Wire)– Yumanity Therapeutics , a company focused on protecting the vitality of the mind by discovering and developing transformative brain-penetrating small molecule drugs to treat neurodegenerative diseases, today announced that the first subject cohort has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of YTX-7739 in healthy volunteers.
YTX-7739, the company’s lead investigational therapy, is designed to inhibit Stearoyl-CoA-Desaturase (SCD), a validated biologic target that has recently shown potential in neurodegenerative diseases by protecting cells from a-synuclein toxicity, a major driver of Parkinson’s disease.
-Developing effective therapies for patients with devastating neurodegenerative diseases has been challenging because too few hypotheses and novel targets have been explored,” said Kenneth Rhodes, Ph. D., chief scientific officer at Yumanity Therapeutics.
About YTX-7739 YTX-7739 is Yumanity Therapeutics’ proprietary lead investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target that plays an important and previously unrecognized role in the neurotoxicity caused by the a-synuclein protein, a major driver of Parkinson’s disease and related neurodegenerative disorders.
Formed in 2014 by renowned biotech industry leader, Tony Coles, M. D., and protein folding science pioneer, Susan Lindquist, Ph. D., the company is focused on discovering disease-modifying therapies for patients with Parkinson’s disease and related disorders, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease.
|disease||MESH||amyotrophic lateral sclerosis|
|disease||DOID||amyotrophic lateral sclerosis|
- Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease
- The endotoxin hypothesis of neurodegeneration.